Document Detail


Benefits from growth hormone therapy after bariatric surgery.
MedLine Citation:
PMID:  19550390     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is increasing interest in the use of bariatric surgery to achieve weight loss in individuals with severe obesity. However, there are concerns over the loss of lean body mass (LBM) following surgery in individuals who have functional growth hormone (GH) deficiency related to their obesity. We discuss here the results of an open-label study in which we studied the efficacy of GH treatment to prevent loss of LBM and metabolic disturbances in 24 women with functional severe GH deficiency who were undergoing laparoscopic adjustable gastric banding for severe obesity. Participants were randomized to standard care (including a dietary restriction programme) with or without GH treatment, and were studied for 6 months. Overall, weight loss and reductions in waist circumference were similar in the two groups. GH treatment was associated with a significant decrease in fat mass and a significantly smaller decrease in LBM, as well as improvements in insulin sensitivity, and lipid profile.
Authors:
Silvia Savastano
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Pediatric endocrinology reviews : PER     Volume:  6 Suppl 4     ISSN:  1565-4753     ISO Abbreviation:  Pediatr Endocrinol Rev     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-24     Completed Date:  2009-08-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101202124     Medline TA:  Pediatr Endocrinol Rev     Country:  Israel    
Other Details:
Languages:  eng     Pagination:  540-4     Citation Subset:  IM    
Affiliation:
Department of Molecular and Clinical Endocrinology and Oncology, University Federico II, Naples, Italy. sisavast@unina.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Bariatric Surgery*
Female
Gastroplasty
Human Growth Hormone / deficiency*,  therapeutic use*
Humans
Insulin Resistance
Middle Aged
Obesity / complications*,  surgery*
Weight Loss
Chemical
Reg. No./Substance:
12629-01-5/Human Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth hormone deficiency after traumatic brain injury in adults: when to test and how to treat?
Next Document:  Adherence remains a challenge for patients receiving growth hormone therapy.